Loading video...

Video Failed to Load

Go Home

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Solid Biosciences's CEO Bo Cumbo discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy. $SLDB Full video:

BiotechTV's profile picture

BiotechTV

11,568 subscribers

42,139 views โ€ข 1 year ago โ€ขvia X (Twitter)

Science & TechnologyNews & PoliticsHealth & Wellness
LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:
7:20

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Prime Medicine's new CEO Allan Reine walks us through the prime editing company's new focused pipeline. $PRME Full video:

BiotechTV

37,174 views โ€ข 1 year ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:
4:58

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib. $CRVS Full video:

BiotechTV

24,695 views โ€ข 6 months ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 views โ€ข 1 month ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target. Full video:
6:12

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target. Full video:

BiotechTV

14,073 views โ€ข 1 year ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 views โ€ข 1 year ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:
3:36

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: With three approved products and filings for more over the near term, Axsome Therapeutics's CEO describes the scale and reach this company is building in the CNS space. $AXSM Full video:

BiotechTV

20,894 views โ€ข 1 year ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 views โ€ข 10 months ago

Today, the FDA approved the first gene therapy treatment for Duchenne Muscular Dystrophy. This groundbreaking treatment, developed here at Nationwide Childrenโ€™s, is giving boys like Easton and Connor a future full of hope and possibilities. Watch their incredible stories.
4:09

Today, the FDA approved the first gene therapy treatment for Duchenne Muscular Dystrophy. This groundbreaking treatment, developed here at Nationwide Childrenโ€™s, is giving boys like Easton and Connor a future full of hope and possibilities. Watch their incredible stories.

Nationwide Children's Hospital

75,898 views โ€ข 3 years ago

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:
4:40

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes. $SANA Full video:

BiotechTV

19,210 views โ€ข 6 months ago

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:
4:17

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases. Full video:

BiotechTV

18,780 views โ€ข 9 months ago

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Metsera Inc. CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA. $MTSR Full video:
6:06

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Metsera Inc. CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA. $MTSR Full video:

BiotechTV

10,378 views โ€ข 1 year ago

๐€ ๐…๐ข๐ซ๐ฌ๐ญ๐ก๐š๐ง๐ ๐€๐œ๐œ๐จ๐ฎ๐ง๐ญ: Jimi Olaghere's life was changed by the CRISPR based gene therapy CASGEVY. He says there is not enough awareness of or access to these types of therapies in the sickle cell disease community. Full video:
2:50

๐€ ๐…๐ข๐ซ๐ฌ๐ญ๐ก๐š๐ง๐ ๐€๐œ๐œ๐จ๐ฎ๐ง๐ญ: Jimi Olaghere's life was changed by the CRISPR based gene therapy CASGEVY. He says there is not enough awareness of or access to these types of therapies in the sickle cell disease community. Full video:

BiotechTV

21,947 views โ€ข 1 year ago

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:
4:45

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video:

BiotechTV

10,996,439 views โ€ข 2 months ago

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:
10:34

๐€๐’๐†๐‚๐“ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account by Kiran Musunuru. #ASGCT2025 Full video:

BiotechTV

22,275 views โ€ข 1 year ago

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:
4:00

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:

BiotechTV

12,936 views โ€ข 8 months ago

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:
13:02

๐๐ซ๐ข๐ ๐ก๐ญ ๐Œ๐ข๐ง๐๐ฌ: William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron. $VKTX $LLY Full video:

BiotechTV

68,717 views โ€ข 11 months ago

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:
6:11

๐Ž๐Ÿ๐Ÿ-๐“๐š๐ซ๐ ๐ž๐ญ ๐„๐Ÿ๐Ÿ๐ž๐œ๐ญ๐ฌ: BridgeBio Pharma Founder & CEO Neil Kumar and Roivant Sciences CEO Matt Gline discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term. $BBIO $ROIV Watch the full episode:

BiotechTV

11,639 views โ€ข 3 months ago

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:
3:51

๐’๐… ๐‡๐ž๐š๐ฅ๐ญ๐ก๐œ๐š๐ซ๐ž ๐–๐ž๐ž๐ค: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year. $ABVX Full video:

BiotechTV

73,893 views โ€ข 6 months ago

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.
4:50

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

BiotechTV

20,285 views โ€ข 3 months ago